全文获取类型
收费全文 | 34512篇 |
免费 | 2831篇 |
国内免费 | 1564篇 |
专业分类
耳鼻咽喉 | 627篇 |
儿科学 | 414篇 |
妇产科学 | 500篇 |
基础医学 | 2968篇 |
口腔科学 | 581篇 |
临床医学 | 7961篇 |
内科学 | 3853篇 |
皮肤病学 | 238篇 |
神经病学 | 1909篇 |
特种医学 | 1205篇 |
外国民族医学 | 2篇 |
外科学 | 3262篇 |
综合类 | 4951篇 |
预防医学 | 2269篇 |
眼科学 | 257篇 |
药学 | 2261篇 |
72篇 | |
中国医学 | 1287篇 |
肿瘤学 | 4290篇 |
出版年
2024年 | 26篇 |
2023年 | 536篇 |
2022年 | 1063篇 |
2021年 | 1578篇 |
2020年 | 1609篇 |
2019年 | 1198篇 |
2018年 | 1173篇 |
2017年 | 1275篇 |
2016年 | 1286篇 |
2015年 | 1230篇 |
2014年 | 2460篇 |
2013年 | 3021篇 |
2012年 | 2185篇 |
2011年 | 2256篇 |
2010年 | 1888篇 |
2009年 | 1689篇 |
2008年 | 1783篇 |
2007年 | 1822篇 |
2006年 | 1572篇 |
2005年 | 1303篇 |
2004年 | 1093篇 |
2003年 | 1032篇 |
2002年 | 835篇 |
2001年 | 839篇 |
2000年 | 632篇 |
1999年 | 575篇 |
1998年 | 412篇 |
1997年 | 407篇 |
1996年 | 313篇 |
1995年 | 326篇 |
1994年 | 263篇 |
1993年 | 159篇 |
1992年 | 153篇 |
1991年 | 109篇 |
1990年 | 118篇 |
1989年 | 78篇 |
1988年 | 78篇 |
1987年 | 57篇 |
1986年 | 39篇 |
1985年 | 65篇 |
1984年 | 70篇 |
1983年 | 41篇 |
1982年 | 48篇 |
1981年 | 40篇 |
1980年 | 43篇 |
1979年 | 47篇 |
1978年 | 23篇 |
1977年 | 14篇 |
1976年 | 15篇 |
1974年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Saudi Pharmaceutical Journal》2022,30(6):669-678
BackgroundIschemia reperfusion (I/R) play an imperative role in the expansion of cardiovascular disease. Sinomenine (SM) has been exhibited to possess antioxidant, anticancer, anti-inflammatory, antiviral and anticarcinogenic properties. The aim of the study was scrutinized the cardioprotective effect of SM against I/R injury in rat.MethodsRat were randomly divided into normal control (NC), I/R control and I/R + SM (5, 10 and 20 mg/kg), respectively. Ventricular arrhythmias, body weight and heart weight were estimated. Antioxidant, inflammatory cytokines, inflammatory mediators and plasmin system indicator were accessed.ResultsPre-treated SM group rats exhibited the reduction in the duration and incidence of ventricular fibrillation, ventricular ectopic beat (VEB) and ventricular tachycardia along with suppression of arrhythmia score during the ischemia (30 and 120 min). SM treated rats significantly (P < 0.001) altered the level of antioxidant parameters. SM treatment significantly (P < 0.001) repressed the level of creatine kinase MB (CK-MB), creatine kinase (CK) and troponin I (Tnl). SM treated rats significantly (P < 0.001) repressed the tissue factor (TF), thromboxane B2 (TXB2), plasminogen activator inhibitor 1 (PAI-1) and plasma fibrinogen (Fbg) and inflammatory cytokines and inflammatory mediators.ConclusionOur result clearly indicated that SM plays anti-arrhythmia effect in I/R injury in the rats via alteration of oxidative stress and inflammatory reaction. 相似文献
2.
中国传统运动疗法作为极具特色的康养健身运动疗法,在防病治病中的宝贵价值备受国际康复医学界关注。而慢性筋骨病是骨伤科临床中的常见病、多发病与疑难杂病,临床呈现出“一大五多五高”的特征,成为当前重大的健康问题与临床防治研究课题。本文通过深入探究中国传统运动疗法特点以及其在慢性筋骨病康复中的应用原理、原则及优势作用,提出以传统运动疗法为依托,构建慢性筋骨病防病治病应用方法模式;以三因制宜为指导,构建医院-社区-团体-患者为一体的康复管理模式;以“治未病”工程为支撑,构建慢性筋骨病管理信息资源共享平台模式;为切实提高防、控、治的能力与水平找准抓手与路径,为构建慢性筋骨病康复模式提供新的思路与方向。 相似文献
3.
目的分析28例原发性卵黄囊瘤(YST)患者的CT表现。方法选择2015年2月至2019年12月收治的28例YST患者的临床资料进行回顾性分析,8例YST患者入院后均予以CT检查,然后对患者的CT影像学特征和临床资料数据进行分析比较。结果本研究中28例YST患者肿瘤位于性腺的有17例(60.71%),其中位于睾丸、卵巢处的分别有7例、10例,占比分别为60.71%、41.18%,均为单侧发病;9例(39.29%)位于性腺外,其中位于骶尾部、前纵隔、阴道的分别有6例、2例、1例,占比分别为66.67%、22.22%、11.11%。CT检测可见肿瘤"浅分叶",且呈"椭网形",18例(64.29%)肿瘤边界较为清晰,9例(32.14%)呈"深分叶状"形态不规则;8例(28.57%)边界模糊,肿瘤大小分析可见,肿瘤位于前纵隔、卵巢的相对较大,位于阴道、睾丸、骶尾部的相对较小。28例YST患者中,单纯型21例YST(75.00%),混合型7例(25.00%)。结论原发性卵黄囊瘤进行CT检测尤为重要,其CT表现具有一定特征性,可为临床治疗提供一定的依据。 相似文献
4.
5.
6.
7.
BackgroundPost-operative elderly hip fracture patients require significant rehabilitation. Nandrolone is an anabolic steroid used to promote muscle growth. This study aims to examine the effect of nandrolone in improving rehabilitation and quality of life in elderly female patients with hip fractures undergoing hemiarthroplasty.MethodsThis is a double-blinded prospective randomized-controlled-trial consisting of female patients above the age of 65 with an isolated neck of femur fracture planned for a hip hemiarthroplasty. Participants were randomized into two arms of the study – 50 mg intramuscular nandrolone vs normal saline placebo administered on post-operative day 0, and weeks 2, 6 and 12. The participants were followed up across a 1-year period following the surgery. Clinical outcomes such as time taken to achieve rehabilitation milestones, distance of ambulation and thigh muscle girth, and functional scoring with SF-36 questionnaire were recorded at intervals of 2, 6 and 12 weeks, 6 months and 1 year following the surgery.ResultsThere were a total of 23 subjects with 11 in the steroid group and 12 in the placebo group. There was no significant difference in demographics and injury patterns between both groups. There was no significant difference for time taken to achieve various rehabilitation milestones and distance of ambulation. SF-36 scores on discharge and at 1-year follow-up mark were comparable. There was no difference in the complication rate between both groups.ConclusionIntra-muscular Nandrolone after hip surgery in elderly female patients does not result in short to mid-term improved rehabilitation or functional outcomes. Nandrolone did not result in increased short-term complications after hip surgery.Level of evidenceI. 相似文献
8.
9.
《Saudi Pharmaceutical Journal》2022,30(5):595-604
Anthrax is a zoonotic infection caused by the gram-positive, aerobic, spore-forming bacterium Bacillus anthracis. Depending on the origin of the infection, serious health problems or mortality is possible. The virulence of B. anthracis is reliant on three pathogenic factors, which are secreted upon infection: protective antigen (PA), lethal factor (LF), and edema factor (EF). Systemic illness results from LF and EF entering cells through the formation of a complex with the heptameric form of PA, bound to the membrane of infected cells through its receptor. The currently available anthrax vaccines have multiple drawbacks, and recombinant PA is considered a promising second-generation vaccine candidate. However, the inherent chemical instability of PA through Asn deamidation at multiple sites prevents its use after long-term storage owing to loss of potency. Moreover, there is a distinct possibility of B. anthracis being used as a bioweapon; thus, the developed vaccine should remain efficacious and stable over the long-term. Second-generation anthrax vaccines with appropriate adjuvant formulations for enhanced immunogenicity and safety are desired. In this article, using protein engineering approaches, we have reviewed the stabilization of anthrax vaccine candidates that are currently licensed or under preclinical and clinical trials. We have also proposed a formulation to enhance recombinant PA vaccine potency via adjuvant formulation. 相似文献
10.
Maja Popovic Gorana Matovina-Brko Masa Jovic Lazar S Popovic 《World journal of clinical oncology》2022,13(1):28-38
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with inter mediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozan tinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment. 相似文献